My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 194

    1.

    Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

    Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S.

    Diabetes. 2003 Apr;52(4):910-7.PMID: 12663460 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.

    Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T.

    Diabetes. 1998 Dec;47(12):1841-7.PMID: 9836514 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

    Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML.

    J Biol Chem. 2003 Sep 5;278(36):34268-76. Epub 2003 Jun 11.PMID: 12805374 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.

    Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, Rajanayagam O, Garnes KT, Levinson SH, Xu HE, Schwabe JW, Willson TM, O'Rahilly S, Chatterjee VK.

    Endocrinology. 2004 Apr;145(4):1527-38. Epub 2003 Dec 4.PMID: 14657011 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.

    Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2412-21. Review.PMID: 12788836 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle.

    Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, Furler SM, Chisholm DJ, Cooney GJ.

    J Clin Endocrinol Metab. 2000 Nov;85(11):4293-7.PMID: 11095470 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy.

    Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamäki A, Nyman T, Vidal H, Hamsten A, Yki-Järvinen H.

    AIDS. 2003 Aug 15;17(12):1753-62.PMID: 12891061 [PubMed - indexed for MEDLINE]Related articles

    8.

    Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.

    He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM.

    Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7. Epub 2003 Dec 5.PMID: 14660788 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.

    Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S.

    Ann Intern Med. 2004 May 18;140(10):786-94.PMID: 15148065 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics.

    Chatterjee VK.

    Horm Res. 2003;60 Suppl 3:51-5. Review.PMID: 14671397 [PubMed - indexed for MEDLINE]Related articles

    11.

    Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor gamma resistance.

    Chatterjee VK.

    Biochem Soc Trans. 2001 May;29(Pt 2):227-31. Review.PMID: 11356159 [PubMed - indexed for MEDLINE]Related articles

    12.

    Insulin resistance and its treatment by thiazolidinediones.

    Lebovitz HE, Banerji MA.

    Recent Prog Horm Res. 2001;56:265-94. Review.PMID: 11237217 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor gamma interactively influence insulin sensitivity and body composition in males.

    Damcott CM, Moffett SP, Feingold E, Barmada MM, Marshall JA, Hamman RF, Ferrell RE.

    Metabolism. 2004 Mar;53(3):303-9.PMID: 15015141 [PubMed - indexed for MEDLINE]Related articles

    14.

    A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

    Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF.

    Diabetes. 2002 Apr;51(4):1083-7.PMID: 11916929 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.

    Itoh H, Doi K, Tanaka T, Fukunaga Y, Hosoda K, Inoue G, Nishimura H, Yoshimasa Y, Yamori Y, Nakao K.

    Clin Exp Pharmacol Physiol. 1999 Jul;26(7):558-60.PMID: 10405788 [PubMed - indexed for MEDLINE]Related articles

    16.

    Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

    Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S.

    Am J Physiol Endocrinol Metab. 2004 Apr;286(4):E560-7. Epub 2003 Nov 18.PMID: 14625208 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice.

    Olswang Y, Cohen H, Papo O, Cassuto H, Croniger CM, Hakimi P, Tilghman SM, Hanson RW, Reshef L.

    Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):625-30. Epub 2002 Jan 15.PMID: 11792850 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.

    Hegarty BD, Furler SM, Oakes ND, Kraegen EW, Cooney GJ.

    Endocrinology. 2004 Jul;145(7):3158-64. Epub 2004 Apr 1.PMID: 15059948 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

    Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S.

    Nature. 1999 Dec 23-30;402(6764):880-3.PMID: 10622252 [PubMed - indexed for MEDLINE]Related articles

    20.

    C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor gamma expression in adipose tissue of familial combined hyperlipidemia patients.

    Ylitalo K, Nuotio I, Viikari J, Auwerx J, Vidal H, Taskinen MR.

    Metabolism. 2002 May;51(5):664-70.PMID: 11979403 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity